Seeking Alpha

Regenxbio's Vector Technology Will Change Gene Therapy

Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

Genenta: Lentiviral Vector Technology Early Survival GBM Signal Warrants Buy Rating

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.
Yahoo Finance

Viral Vector and Plasmid DNA Technologies Market Outlook 2024-2028: Innovations, Technological Advances and Product Launches from Leading Companies

Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for viral ...
Yahoo Finance

Viral Vector Vaccines Strategic Business Research Report 2025 | Market to Reach $893.2 Million by 2030 - Pandemic-Era Acceleration of Vaccine Technologies Continues to Drive ...

Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Viral Vector Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Viral Vector ...
GEN

Vector Production Would Benefit from Purpose-Built Processing Technology

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...